Cell cycle progression is facilitated by cyclindependent kinases that are activated by cyclins including cyclin D1 and inactivated by cyclindependent kinase inhibitors (CDKIs) such as p27. Our previous studies have demonstrated decreased p27 expression in both papillary and more aggressive carcinomas of the thyroid compared to thyroid adenoma and almost similar level of cyclin D1 expression between thyroid adenoma and papillary carcinoma. These results indicate that CDKIs may have an important role in the carcinogenesis of the thyroid and that they probably have a limited role in malignant progression of the thyroid cancer. The role of cyclin D1 in malignant progression of thyroid carcinoma has yet to be established. We studied the expression of cyclin D1 by immunohistochemistry in 34 cases of conventional papillary carcinoma (CPC), 10 cases of minimally invasive follicular carcinoma (MIFC), and 32 cases of more aggressive thyroid carcinoma (ATC), which included 11 tall cell variants, one columnar cell variant of papillary carcinoma, seven insular carcinomas, and 13 anaplastic carcinomas. Cyclin D1 staining was classified by staining score as 0, negative; 1؉, less than 25%; 2؉, 25 to 50%; and 3؉, more than 50% tumor cells staining positive. Kruskal-Wallis oneway ANOVA and Wilcoxon Rank Sum/MannWhitney U Test was used to assess the difference in the expression of cyclin D1 between the study groups. Twenty-eight out of the 34 CPCs were cyclin D1 positive, 24 (70%) were 1؉, 3 (9%) were 2؉, and one (3%) were 3؉ positive. Seven of 10 MIFCs were cyclin D1 positive, five (71%) were 1؉, and the remaining two (29%) were 2؉ positive. On the other hand, 28 of 32 ATCs showed cyclin D1 immunostaining. Of these, three (9%) were 1؉, five (13%) were 2؉, and 20 (63%) were 3؉ positive. This study demonstrates a significant overexpression of cyclin D1 in ATC compared CPC (P < .001) and MIFC (P < .005), suggesting that the cyclin D1 expression may play a role in tumor progression and may have prognostic significance in thyroid cancer.
The loss of regulatory control of the cell cycle, leading to unrestrained cell proliferation, is a hallmark of cancer. Cyclins, the regulatory subunits of cyclindependent kinases (CDKs), control the passage of proliferating cells through key checkpoints in the cell cycle (1-3, for review). The deregulation of cyclin expression results in the loss of control of normal growth. The linkage between oncogenesis and cyclins was made with the discovery of two cyclins in tumors. Cyclin A gene was found to be the integration site of a fragment of the hepatitis B virus genome in hepatocellular carcinoma (4) . In parathyroid adenomas, the PRAD1 (cyclin D) gene is overexpressed as a result of a pericentrimeric inversion of chromosome 14, which places the PRAD1 gene under control of the parathyroid hormone promoter gene (5) (6) (7) . PRAD1 is also activated by t (11, 14) translocation in mantle cell lymphoma due to the placement of cyclin D1 gene next to an immunoglobulin heavy chain enhancer gene (8) . Overexpression of the cyclin D1 gene has been shown in some breast carcinomas, hepatocellular carcinomas, esophageal carcinomas, head and neck squamous cell carcinomas, and thyroid carcinomas (9 -19) . Other cyclins have also been implicated in tumorigenesis. Cyclin D2 and E are overexpressed in colorectal carcinomas (20) . Cyclin E has been found to be overexpressed in breast carcinomas and may be associated with more advanced stages of breast cancer (21) . The overexpression of positive growth regulators may overwhelm the arrest mechanism of the normal cell cycle and lead to uncontrolled cell proliferation (1) .
However, the overexpression of positive growth regulators may not be the only mechanism by which cell proliferation is stimulated. Alternatively, the underexpression of negative growth regulators, such as the cyclin-dependent kinase inhibitors (CDKIs), can have the same effect on the cell cycle. p27 negatively controls the cell transition from quiescence to proliferation by inhibiting the cyclin-CDK complexes (1) . Our previous studies have demonstrated a decreased p27 expression in both papillary and more aggressive carcinomas of the thyroid compared to their benign counterparts (22) (23) (24) . We also demonstrated a similar level of cyclin D1 expression in papillary carcinoma and follicular adenoma (24) . The results of these studies indicate that cyclin-dependent kinase inhibitors may have a more important role than cyclins in thyroid carcinogenesis and that they probably play a limited role in the malignant progression of thyroid cancer. Although some studies (16 -17) have shown cyclin D1 overexpression in thyroid carcinoma compared to benign lesions, its role in the malignant progression of thyroid cancer is yet to be established. We hypothesize that although the underexpression of p27 is important for the malignant transformation of the thyroid, the overexpression of cyclins, such as cyclin D1, may lead to progression and dedifferentiation of thyroid carcinoma. The aim of this study is to determine if differences in cyclin D1 immunostaining can aid in the differentiation of indolent from more aggressive thyroid carcinomas (ATCs). Furthermore, such immunostaining may suggest possible mechanisms for thyroid malignant progression.
MATERIALS AND METHODS

Tissue Specimens Studied
Thirty-four cases of conventional papillary carcinoma (CPC), 10 cases of minimally invasive (encapsulated) follicular carcinoma, and 32 cases of more aggressive carcinoma of the thyroid (including 11 tall cell variants and one columnar cell variant of papillary carcinoma, seven insular carcinomas, and 13 anaplastic carcinomas) were selected from the surgical pathology files of UMass Memorial (University campus) Medical Center, Worcester, Massachusetts (diagnosed between 1992 and 1997), and Mayo Clinic, Rochester, Minnesota (diagnosed between 1960 and 1993). All the cases were reviewed by at least two pathologists to confirm the diagnoses. The diagnosis of CPC, MIFC, and more aggressive carcinoma was based on established histologic criteria (25) . All 10 MIFCs were encapsulated tumors with nine showing focal transcapsular invasion and one showing a focus of vascular invasion. Paraffin blocks were selected for immunohistochemistry to include both the tumor and the rim of normal thyroid tissue around it, the latter to serve as a control. Normal thyroid tissue was seen in all 76 cases.
Immunohistochemistry
All thyroid resection specimens in this study were fixed in 10% buffered formalin and paraffin embedded by routinely processing through a VIP Tissue Tek processor (Miles Scientific, Naperville, IL). Sections were cut at a thickness of 4 m, heated at 60°C for 30 min, then deparaffinized and hydrated through a series of xylene and alcohol baths before staining. The slides were microwaved with a proprietary antigen retrieval solution (citrate buffer) (BioTek Solutions, Santa Barbara, CA) for 5 min in an 800 watt microwave oven. After replenishment of this solution, the slides were microwaved again for an additional 5 min and then allowed to cool for 20 min. Immunohistochemical staining was performed with monoclonal anti-cyclin D1 antibody (Novocastra/Vector, Burlingame, CA), at dilution of 1:20, using a standard avidin/biotin complex (ABC) method as implemented on a Techmate 1000 (BioTek) automated immunostainer. The staining procedure consisted of a 45-min incubation in the primary antibody, followed by brief buffer washes, and then incubation in a cocktail of biotinylated anti-mouse IgG/IgM (BioTek) for 30 min. The slides were then washed, incubated in avidin/biotin complex (BioTek) for 30 min, washed, and then reacted with diaminobenzidine and hydrogen peroxide to visualize the end product. The sections were counterstained with hematoxylin. A breast cancer known to express cyclin D1 served as positive control for cyclin D1. For negative control, nonimmune serum was substituted for primary antibody.
Evaluation of Immunostaining
Immunostained sections were evaluated by estimating the percentage of tumor cells stained with monoclonal anti-cyclin D1 antibody without knowledge of the pathological diagnosis. Only a distinct brown nuclear staining of tumor cells was considered as positive. The nuclear staining in the normal thyroid tissue surrounding the tumor was used as an internal negative control for cyclin D1. The sections were examined on a Olympus microscope using an eyepiece graticule (Olympus, Tokyo, Japan) to facilitate cell counting. The sections were examined first under low magnification (50ϫ and 100ϫ) to see the overall staining pattern and later at a higher magnification (400ϫ), at which a minimum of 1000 cells were counted using the eyepiece graticule. The percentage of positive cells was then calculated and positive staining scored as: 1ϩ ϭ less than 10%, 2ϩ ϭ 11 to 50% and 3ϩ ϭ more than 50% tumor cells stained positive.
Data Analysis
In order to establish a difference in cyclin D1 expression among MIFC, CPC, and the more ATCs, Kruskal-Wallis one-way ANOVA was used. Following determination of significance, pair-wise comparisons were performed using the Wilcoxon Rank Sum/Mann-Whitney U Test (26) . Statistical significance was defined at the level of P Ͻ .05 (twotailed), divided evenly among multiple comparisons.
RESULTS
The normal thyroid tissue in all 76 cases was negative for cyclin D1. The number of cases positive for cyclin D1 along with the score of nuclear staining is summarized in Table 1 . Twenty-eight out of 34 CPCs were cyclin D1 positive, 24 (70%) were 1ϩ (Fig. 1A) , 3 (9%) were 2ϩ, and one (3%) was 3ϩ positive. Of the 10 minimally MIFCs, seven were cyclin D1 positive. Of these, five (71%) were 1ϩ, and the remaining two (29%) were 2ϩ positive. On the other hand, 28 out of 32 more ATCs showed cyclin D1 immunostaining. Of these, three (9%) were 1ϩ, five (13%) were 2ϩ, and 20 (63%) were 3ϩ positive. The degree of cyclin D1 expression was significantly higher in histologically more aggressive carcinomas compared to both conventional papillary thyroid carcinomas (P Ͻ .001) and MIFCs (P Ͻ .005). There was no significant difference in cyclin D1 expression between MIFCs and CPCs (P ϭ .8). Tall cell/ columnar cell variants of papillary carcinoma (TCV/CCV) showed 3ϩ expression of cyclin D1 in 8 of 12 (66%) cases (Fig. 1B) and the remaining four cases showed 2ϩ, 1ϩ positive, and negative expression of cyclin D1 in 2, 1, and 1 case, respectively. Insular carcinoma demonstrated 3ϩ expression of cyclin D1 in four of seven (57%) cases (Fig. 1C) , the remaining three cases showed 2ϩ staining in 2, and 1ϩ staining in one case. Anaplastic carcinoma demonstrated 3ϩ cyclin D1 staining in 8 of 13 (62%) cases (Fig. 1D) , one case each was 2ϩ and 1ϩ positive, and the remaining three cases were cyclin D1 negative. It was interesting to note that the giant cell nuclei of anaplastic carcinoma, giant cell type, demonstrated stronger cyclin D1 staining compared to the nuclei of the surrounding mononuclear tumor cells, indicating that the overexpression of cyclin D1 may be related to the formation of the tumor giant cells in anaplastic carcinoma.
DISCUSSION
Malignant transformation as a result of uncontrolled cell proliferation may result from the deregulation of cyclins and/or CDKIs. Increased expression of the cell cycle up-regulators such as cyclins or reduced expression of the cell cycle downregulators such as CDKIs may contribute to tumor formation (1-3). Our previous studies have suggested that reduced expression of p27, plays a more important role than cyclin D1 in thyroid carcinogenesis; however, p27 may have a limited role in malignant progression of thyroid cancer (22) (23) (24) . To determine whether cyclin D1 overexpression was involved in thyroid malignant progression, we examined 34 cases of CPC of the thyroid, 10 cases of MIFC, and 32 cases of more aggressive carcinomas of the thyroid using immunohistochemistry. Our study demonstrates a significant overexpression of cyclin D1 in more aggressive carcinomas compared to the CPC and the minimally invasive (encapsulated) follicular carcinoma of the thyroid, suggesting that the cyclin D1 expression may play a role in tumor progression and may have prognostic significance.
The CPC and minimally invasive (encapsulated) follicular carcinoma are both well-differentiated thyroid carcinoma with indolent behavior and excellent prognosis (25) . Tall cell and columnar cell variants of papillary carcinoma tend to occur in older patients and are often larger tumors with an increased incidence of vascular invasion and frequent extrathyroidal extension (27, 28) . Insular carcinoma is a poorly differentiated carcinoma with an intermediate morphology and clinical behavior between the differentiated (papillary) carcinoma of the thyroid and anaplastic carcinoma (29, 30) . Anaplastic (undifferentiated) carcinoma of the thyroid PC, Papillary carcinoma; FC, Follicular carcinoma; TCV, Tall cell variant; CCV, Columnar cell variant. P Ͻ .001, which assessed the difference of cyclin D1 expression between conventional PC and more aggressive (TCV/CCV PC, insular and anaplastic) carcinomas of the thyroid. P Ͻ .005, which assessed the difference of cyclin D1 expression between minimally invasive FC and more aggressive (TCV/CCV PC, insular and anaplastic) carcinomas of the thyroid.
often presents with fast-growing neck mass and is a highly malignant tumor. Most ATCs including insular and anaplastic carcinoma are thought to have arisen from a preexisting, well-differentiated papillary or follicular carcinoma (25) . Several oncogenes or tumor suppressor genes have been shown to contribute to the malignant progression and dedifferentiation of thyroid cancer (31) (32) (33) (34) (35) . The expression of bcl-2 has been observed in differentiated and poorly differentiated thyroid carcinoma and to a lesser degree in anaplastic carcinoma (31, 32) ; p53 expression on the other hand is seen more often in poorly differentiated and anaplastic carcinoma compared to differentiated thyroid carcinoma (33) (34) (35) . Mutation of the p53 gene has been found in a high percentage of anaplastic carcinomas. This mutation is not present in the residual differentiated papillary carcinoma component suggesting that p53 mutation occurred after the development of the papillary carcinoma and plays a key role in the malignant progression of the tumor (33) (34) (35) . The overexpression of cyclin D1 may contribute to cell proliferation and to subsequent mutations of the tumor suppressor gene, p53, by facilitating the quiescent cells entering to and passing through the cell cycle.
Cyclin D1 forms a multimer complex with cyclindependent kinase (CDK), which facilitate transition through the restriction point of cell cycle by inactivation of the retinoblastoma tumor-suppresser protein (pRb) as a result of its hyperphosphorylation by CDK. Hyperphosphorylation of pRb leads to the release of E2F transcription factors and other proteins from their complexes with pRb, which activates genes coding for positive regulators of cell proliferation (1) (2) (3) . Constitutive overexpression of cyclin D1 caused by chromosomal abnormalities is seen in neoplasms involving parathyroid gland, lymph node, and liver (4 -8) . However, in a subset of breast carcinoma cyclin D1 protein overexpression has been seen in the absence of amplification of the cyclin D1 gene, suggesting that gene amplification is not the only mechanism that results in increased protein expression (36) . Overexpression of cyclins may also be due to increased RNA/protein stability, and due to the increased sensitivity of tumor cell to external stimulating signals such as hormones (37, 38) .
Our recent studies indicate a positive correlation between the expression of eukaryotic translation initiation factors 4E and 2␣ (eIF-4E and eIF-2␣) in thyroid cancer progression (39) . We and others have found earlier that overexpression of eIF-4E causes increased expression of cyclin D1 in NIH T3 cells and in colonic neoplasms (40 -42) . Increased expression of eukaryotic translation initiation fac- tors eIF-4E and eIF-2␣ induced by c-myc and other oncogenes has been described previously (43, 44) . Further studies are needed to determine the oncogenes that cause an increase in cyclin D1 expression through the translation initiation pathway in more aggressive carcinomas of the thyroid.
In summary, there is a significant overexpression of cyclin D1 in more ATCs compared to the CPC and MIFC of the thyroid, suggesting that cyclin D1 expression may play a role in tumor progression and may have prognostic significance.
